A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Influenza Clinical Trial

Official title:

A Double-blind, Randomized, Placebo-controlled, Comparative, Multicenter Phase III Clinical Trial to Study the Clinical Efficacy and Safety of XC221, Tablets, 100 mg in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05544916
• Other study ID #: XC221-03-04-2022
• Status: Completed
• Phase: Phase 3
• Start date: August 5, 2022
• Est. completion date: May 4, 2023

Study information

• Verified date: October 2023
• Source: Valenta Pharm JSC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of the study was to evaluate the effectiveness of XC221, tablets, at a dose of 200 mg/day compared to placebo in patients with uncomplicated influenza or other acute respiratory viral infections (ARIs).

An additional purpose of the study was to evaluate the safety of XC221, tablets, at a dose of 200 mg/day compared to placebo in patients with uncomplicated influenza or other ARIs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 260
• Est. completion date: May 4, 2023
• Est. primary completion date: February 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Men and women between the ages of 18 and 65 years inclusive;

2. Presence of written consent to participate in the study in accordance with applicable law;

3. Clinical signs of mild to moderate influenza or other acute respiratory infections (ARIs): an increase in body temperature, measured at the axilla, with a value between 38.0 °C and 39.5 °C, inclusive, during the current illness and without taking antipyretics within the last 8 h at the time of screening; at least one respiratory manifestation of influenza or other ARI (cough, runny nose/ stuffy nose, sore throat) of at least 2 points on a 4-point scale; at least one systemic manifestation of influenza or other ARI (headache, muscle pain, chills/sweating, fatigue) of at least 2 points on a 4-point scale.

4. No indication for hospitalization at the time of enrollment in the study;

5. Duration of illness from manifestation of symptoms to the first dose of study drug/placebo not more than 48 hours;

6. Negative pregnancy test for women of preserved reproductive potential;

7. Consent to use adequate contraceptive methods throughout the study and for 30 days after study completion;

8. Ability to understand the requirements for study participants, to give written consent to participate in the study (including the use and communication of patient health information relevant to the study) and to comply with the procedures of the study protocol.

Exclusion Criteria:

1. Pregnant and breastfeeding women;

2. Known hypersensitivity to the study drug, including the active and/or excipients.

3. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption, galactose intolerance;

4. Diagnosis of COVID-19 established or probable at present (based on examination and analysis of epidemiological history);

5. Positive result of rapid test for SARS-CoV-2;

6. Blood oxygen saturation (SpO2) = 95%, respiratory rate = 22/min.

7. Complicated course of influenza or other acute respiratory infections;

8. Participation in any other clinical trial within 90 days prior to the screening period;

9. Known (based on medical history) or suspected alcohol abuse, psychotropic drugs, drug dependence, drug addiction;

10. Presence of mental illness, including a history of mental illness;

11. Clinical suspicion of pneumonia or other bacterial infections (including sinusitis, otitis media, urinary tract infection, meningitis, sepsis, etc.) requiring prescription of antibacterial drugs;

12. Taking antibiotics, antivirals, or immunomodulatory drugs for < 48 h before the study and/or plans to use these groups of drugs (other than the study drug) during the study;

13. Use of systemic, inhaled, or nasal glucocorticosteroids within 30 days prior to the study and/or plans to use glucocorticosteroids (except topical cutaneous agents) during the study;

14. Failure to withdraw for the duration of the study other medications that may affect the outcome of this study, such as antiviral medications, or medications that are incompatible with the study therapy;

15. Any cardiovascular, renal, hepatic, gastrointestinal, endocrine or nervous system diseases, severe decompensated chronic (including chronic kidney disease and chronic liver disease) or acute diseases or any other condition/disease that, in the opinion of the investigator, would make it unsafe for the patient to participate in the study;

16. Any vaccination of the patient within 90 days prior to inclusion in the study;

17. Diabetes mellitus in decompensation;

18. Obesity of 2-3 degrees (body mass index of 35 kg/m2 or more).

19. Patients who have undergone surgery within 30 days prior to the Screening Visit and patients who are scheduled to undergo surgery, including diagnostic procedures, or a hospital stay during the study;

20. The presence of cancer, including a history of cancer (with the exception of a cured tumor with sustained remission for more than 5 years);

21. The presence of HIV infection, tuberculosis, including in the anamnesis;

22. Meningeal syndrome;

23. Disturbance of consciousness (in the form of stunting, soporus, delirium, delirium, etc.).

24. Symptoms of pneumonia and possible acute respiratory distress syndrome (ARDS): cough with foaming sputum with blood, shortening of the pulmonary sound on percussion, a large number of different-caliber wet rales and abundant crepitation on auscultation, a sharp drop in blood pressure, deafness of heart tones and arrhythmia;

25. Patient's refusal to use approved contraception or to completely abstain from sexual intercourse for the duration of study participation, beginning at Visit 1, and for 30 days after completion of study participation;

26. Other reasons that, in the opinion of the investigator, prevent the patient from participating in the study or create an unreasonable risk.

Withdrawal Criteria:

1. Patient's desire to stop participating in the study (withdrawal of informed consent). Each patient has the right to stop participating in the study at any time without giving a reason. Withdrawal from the study will not affect the medical care provided to the patient in the future.

2. The decision by the research physician that the patient should be excluded is in the patient's own interest;

3. The need to prescribe etiotropic or any other treatment prohibited in the study, as determined by the investigating physician.

4. Patient refuses to cooperate with the investigator or is undisciplined;

5. Causes/occurrence during the study of situations that threaten patient safety (e.g., hypersensitivity reactions, serious adverse events, etc.);

6. Inclusion of a patient in the study with inclusion/inclusion criteria not met (prior to randomization);

7. Significant treatment failure; Significant failure is defined as a) skipping study drug/placebo for 2 consecutive days or more or b) taking, in total, < 80% or > 120% of the full course (full course = 10 pills).

8. Positive pregnancy test;

9. A confirmed diagnosis of COVID-19;

10. Occurrence in the course of the study of other reasons that prevent the study according to the protocol.

11. Death of a patient.

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Influenza
• Influenza, Human
• Respiratory Viral Infection
• Virus Diseases

Intervention

Drug:
• XC221
200 mg/day, for 5 days
• Placebo
2 tablets/day, for 5 days

Locations

Country	Name	City	State
Russian Federation	Medical Diagnostic Center "Medexpert", LLC	Engels
Russian Federation	State autonomous health care institution "Engels City Clinical Hospital No. 1"	Engels
Russian Federation	Unimed-C Jsc	Moscow
Russian Federation	Professors' Clinic LLC.	Perm
Russian Federation	"Medical Clinic" Ltd.	Saint Petersburg
Russian Federation	Limited Liability Company "Health Energy"	Saint Petersburg
Russian Federation	Limited Liability Company "Meili"	Saint Petersburg
Russian Federation	Limited Liability Company "Research Center Eco-Security"	Saint Petersburg
Russian Federation	Saint Petersburg State Budgetary Healthcare Institution "City polyclinic No. 112"	Saint Petersburg
Russian Federation	Saint Petersburg State Budgetary Institution of Healthcare "City Pokrovskaya Hospital"	Saint Petersburg
Russian Federation	St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 117"	Saint Petersburg
Russian Federation	St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 4"	Saint Petersburg
Russian Federation	State budgetary institution of health care of the Yaroslavl region "Clinical Hospital No. 2"	Yaroslavl

Sponsors (1)

Lead Sponsor	Collaborator
Valenta Pharm JSC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time (in hours) from the first dose of the drug to the resolution of all of the ARI symptoms/events	Time (in hours) from the first dose of the drug to the resolution of all of the following symptoms/events.; • fever (the day of fever resolution is the first day on which stable normal body temperature is achieved (<37.0°C without the use of antipyretics)); All achieved symptoms/events scores maintained for at least 24 h at 0-1 point: nasal congestion/runny nose; sore throat; cough; muscle aches; headaches; fatigue; chills/sweats. Patients will assess and record the severity of all symptoms on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 10
Secondary	Time to decrease in 24-hour body temperature to = 37.0°C without using antipyretics (number of hours from the first dose of the study treatment to a decrease in 24-hour body temperature to = 37.0°C)	Patients will assess and record body temperature in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents	Day 1 - Day 10
Secondary	Time to nasal congestion/runny nose resolution (number of hours from the first dose of the drug to runny nose/congestion resolution, i.e. the time when the subject rates the 24-hour severity of this symptom at 0-1 point)	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom	Day 1 - Day 10
Secondary	Patient rate with reported nasal congestion/runny nose resolution by day 4 and day 6 from treatment initiation (i.e. patient rate who assessed the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 10
Secondary	Time to sore throat resolution (number of hours from the first dose of the drug to sore throat resolution, i.e. the time when the subject rates the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 10
Secondary	Patient rate with reported sore throat resolution by day 4 and day 6 from treatment initiation (i.e. patient rate who assessed the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 6
Secondary	Time to cough resolution (number of hours from the first dose of the drug to cough resolution, i.e. the time when the subject rates the 24-hour severity of this symptom at 0-1 point.	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 10
Secondary	Patient rate with reported cough resolution by day 4 and day 6 from treatment initiation (i.e. patient rate who assessed the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 6
Secondary	Time to muscle ache resolution (number of hours from the first dose of the drug to the resolution of muscle aches, i.e. the time when the subject rates the 24-hour severity of this symptom at 0-1 point	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 10
Secondary	Patient rate with reported muscle ache resolution by day 4 and day 6 from treatment initiation (i.e. patient rate who assessed the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 6
Secondary	Time to headache resolution (number of hours from the first dose of the drug to headache resolution, i.e. the time when the subject rates the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 10
Secondary	Patient rate with reported headache resolution by day 4 and day 6 from treatment initiation (i.e. patient rate who assessed the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 6
Secondary	Time to fatigue resolution (number of hours from the first dose of the drug to fatigue resolution, i.e. the time when the subject rates the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 10
Secondary	Patient rate with reported fatigue resolution by day 4 and day 6 from treatment initiation (i.e. patient rate who assessed the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 6
Secondary	Time to chills/sweats resolution (number of hours from the first dose of the drug to the resolution of chills/sweats, i.e. the time when the subject rates the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 10
Secondary	Patient rate with reported chills/sweats resolution by day 4 and day 6 from treatment initiation (i.e. patient rate who assessed the 24-hour severity of this symptom at 0-1 point).	Patients will assess and record the severity of symptom on a 4-point scale in the Patient's Diary for 10 days 2 times a day with a 12 ± 2 h interval before the next use of symptomatic agents, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.	Day 1 - Day 6
Secondary	Frequency complications of influenza or other viral upper respiratory tract infections (URIs)	Frequency complications of influenza or other viral URIs: sinusitis, otitis, bronchitis, pneumonia.	Day 1 - Day 10
Secondary	Time till elimination viruses based on qualitative polymerase chain reaction (PCR) test	Time to the first negative PCR test)	Day 1 - Day 10
Secondary	The need for paracetamol or ibuprofen: daily dose on days 1-10	Dose of paracetamol or ibuprofen taken	Day 1 - Day 10
Secondary	Safety and Tolerability: adverse event (AE) rate	Number and frequency of adverse events (AEs) or serious AEs (SAEs)	From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 20 for each participant
Secondary	Safety and Tolerability: AEs associated with the study drug	Number and frequency of AEs or SAEs) associated with the study drug	From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 20 for each participant
Secondary	Safety and Tolerability: treatment discontinuation	Percentage of patients who discontinued treatment due to the occurrence of AEs/SAEs	From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 20 for each participant
Secondary	Safety and Tolerability: hospitalization rate	Frequency of need for hospitalization due to AEs/SAEs	From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 20 for each participant
Secondary	Safety and Tolerability: vital signs - systolic blood pressure (SBP)	SBP, mmHg	Screening, day 4, day 6, day 10, and day 20 of the study or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: vital signs - diastolic blood pressure (DBP)	DBP, mmHg	Screening, day 4, day 6, day 10, and day 20 of the study or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: vital signs - respiratory rate (RR)	RR, breaths per minute	Screening, day 4, day 6, day 10, and day 20 of the study or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: vital signs - heart rate (HR)	HR, beats per minute	Screening, day 4, day 6, day 10, and day 20 of the study or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: vital signs - body temperature	Body temperature, centigrade scale	Screening, day 4, day 6, day 10, and day 20 of the study or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: physical examination results	Physical examination will follow the general rules of internal medicine: general examination, examination of mucous membranes and skin, including palpation of lymph nodes, evaluation of the musculoskeletal system, palpation, percussion, and auscultation of the main organ systems (cardiovascular, respiratory, digestive, and urinary systems) will be performed sequentially.	Screening, day 4, day 6, day 10, and day 20 of the study or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - hemoglobin	Hemoglobin, g/dL	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - red blood cells	Red blood cells, 10^6/uL	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - hematocrit	Hematocrit, %	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - platelets	Platelets, 10^3/uL	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - white blood cells	White blood cells, 10^3/uL	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - erythrocyte sedimentation rate	Erythrocyte sedimentation rate, mm per hour	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - lymphocytes	Lymphocytes, %	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - eosinophils	Eosinophils, %	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - monocytes	Monocytes, %	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - basophils	Basophils, %	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: complete blood count - neutrophils	Neutrophils, % (segmented and stab)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - glucose	Glucose in blood serum, mmol/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - total cholesterol	Total cholesterol in blood serum, mmol/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - triglycerides	Triglycerides in blood serum, mmol/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - total bilirubin	Total bilirubin in blood serum, umol/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - total protein	Total protein in blood serum, g/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - creatinine	Creatinine in blood serum, umol/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - urea	Urea in blood serum, mmol/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - aspartate transaminase (AST)	AST in blood serum, U/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - alanine transaminase (ALT)	ALT in blood serum, U/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - alkaline phosphatase (ALP)	ALP in blood serum, U/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: blood test results - creatine kinase (CK)	CK in blood serum, U/L	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis - specific gravity	Specific gravity of the urine	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis - color	Color of the urine	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis - transparency	Transparency of the urine	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis - pH	pH of the urine	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis - protein	Protein in the urine (g/L)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis - glucose	Glucose in the urine (mmol/L)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis (microscopy) - red blood cells	Red blood cells in the urine (number in sight)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis (microscopy) - white blood cells	White blood cells in the urine (number in sight)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis (microscopy) - epithelial cells	Epithelial cells in the urine (number in sight)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis (microscopy) - cylinders	Cylinders in the urine (number in sight)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis (microscopy) - bacteria	Bacteria in the urine (number in sight)	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation
Secondary	Safety and Tolerability: urinalysis (microscopy) - mucus	Presence of mucus in the urine	Screening, day 6, or on the early termination visit, whichever came first, within 20 days of study participation